Gut-microbiome-derived metabolite · Fact sheet
Urolithin A
Also known as UA · pomegranate-derived postbiotic
Urolithin A has early human evidence for target engagement and selected muscle-endurance outcomes, but it is not an FDA-approved drug for aging, muscle loss, mitochondrial disease, or immune decline. Trials have been small and commonly industry sponsored.
What is Urolithin A?
Urolithin A is a metabolite made when certain gut bacteria process ellagitannins found in foods such as pomegranates and walnuts.
It is studied as a trigger of mitophagy, the cellular process that removes damaged mitochondria.
Benefits & claims
Mitochondrial quality control is relevant to aging, muscle function, and immune-cell biology.
Human studies provide a stronger translational base than many frontier compounds, but sponsor involvement, modest samples, and mixed endpoints call for independent replication.
What the evidence supports
- A controlled older-adult trial reported better muscle endurance and biomarker changes but did not improve its primary walking-distance or ATP-production outcomes over placebo.
- Other sponsored trials report muscle-performance or immune-cell signals that need confirmation in larger independent studies.
Research areas
- Mitophagy and mitochondrial biomarkers
- Muscle endurance and physical performance
- Age-related immune changes
- Healthy-aging biology
Dosage & frequency
Human study contextA defined oral urolithin A product was studied for muscle function in older adults. Mixed outcomes do not establish a longevity prescription.
Randomized older-adult muscle trial
Adults age 65–90
- Amount
- 1,000 mg
- Frequency
- Daily for four months
- Route studied or labeled
- Oral
Primary walking-distance and ATP outcomes did not significantly separate from placebo.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Urolithin A supplementation is different from relying on individual gut microbes to convert dietary precursors.
Interactions & precautions
- The muscle-function trial does not establish a comprehensive drug-interaction profile or compatibility with all mitochondrial supplements.
What is still unresolved
- Durable benefit on major functional or aging outcomes remains uncertain.
Side effects & risks
- Short trials generally reported similar adverse-event rates to placebo, but sample sizes were too small to define uncommon harms.
- Several pivotal human studies involved the ingredient developer or sponsor, a conflict that does not invalidate results but increases the value of independent replication.
- Commercial supplement quality may not match trial material.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceRandomized human studies show biochemical target engagement and some secondary muscle or immune signals. In one older-adult trial, the primary walking-distance and ATP-production outcomes were not significantly better than placebo.
Studies
Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.
Industry-sponsored study of muscle performance and mitochondrial biomarkers.
Early study establishing bioavailability, short-term tolerability, and biomarker effects.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Energy: reported experiences
Less fatigue followed by next-day depletion
A commenter described stronger-feeling muscles and less mental fatigue, followed by feeling depleted the next day.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- 500 mg per exposure, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About twelve exposures; elapsed duration not stated
The author reported severe sleep-disordered breathing, which they thought contributed to the next-day fatigue.
Read the original accountTemporary fatigue with no noticeable benefit
A separate commenter reported increased tiredness that was temporary, without a benefit they could detect.
Amount, frequency, route and duration could not be confirmed for this account.
This is a short individual comment, not the outcome of the surrounding poll or a measure of cellular effects.
Read the original accountMore energy alongside anxiety and a racing heart
An author with ME/CFS described improved energy but persistent anxiety, elevated heart rate and thirst after a short trial.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One week
Other exposures described: Escitalopram; Propranolol started after symptoms; Lorazepam
PCOS, pre-existing illness and subsequent medication changes complicate attribution. The title's claim of nervous-system damage was not clinically verified.
Read the original accountMore energy and perceived strength with several simultaneous changes
A commenter described better energy and strength while taking urolithin A with creatine, receiving hormone replacement and changing diet alongside frequent exercise.
Reported use in this account
- Product
- Urolithin A supplement
- Amount
- 500 mg per day
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Creatine; Hormone replacement therapy; Levothyroxine
This selected account does not isolate urolithin A from creatine, hormone treatment, thyroid treatment, exercise or diet. Product content, outcomes and causation were not independently verified.
Read the original accountSleep: reported experiences
Less fatigue followed by next-day depletion
A commenter described stronger-feeling muscles and less mental fatigue, followed by feeling depleted the next day.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- 500 mg per exposure, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About twelve exposures; elapsed duration not stated
The author reported severe sleep-disordered breathing, which they thought contributed to the next-day fatigue.
Read the original accountMood: reported experiences
More energy alongside anxiety and a racing heart
An author with ME/CFS described improved energy but persistent anxiety, elevated heart rate and thirst after a short trial.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One week
Other exposures described: Escitalopram; Propranolol started after symptoms; Lorazepam
PCOS, pre-existing illness and subsequent medication changes complicate attribution. The title's claim of nervous-system damage was not clinically verified.
Read the original accountFocus: reported experiences
Less fatigue followed by next-day depletion
A commenter described stronger-feeling muscles and less mental fatigue, followed by feeling depleted the next day.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- 500 mg per exposure, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About twelve exposures; elapsed duration not stated
The author reported severe sleep-disordered breathing, which they thought contributed to the next-day fatigue.
Read the original accountStrength: reported experiences
Less fatigue followed by next-day depletion
A commenter described stronger-feeling muscles and less mental fatigue, followed by feeling depleted the next day.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- 500 mg per exposure, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About twelve exposures; elapsed duration not stated
The author reported severe sleep-disordered breathing, which they thought contributed to the next-day fatigue.
Read the original accountMore energy and perceived strength with several simultaneous changes
A commenter described better energy and strength while taking urolithin A with creatine, receiving hormone replacement and changing diet alongside frequent exercise.
Reported use in this account
- Product
- Urolithin A supplement
- Amount
- 500 mg per day
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Creatine; Hormone replacement therapy; Levothyroxine
This selected account does not isolate urolithin A from creatine, hormone treatment, thyroid treatment, exercise or diet. Product content, outcomes and causation were not independently verified.
Read the original accountHeart symptoms: reported experiences
More energy alongside anxiety and a racing heart
An author with ME/CFS described improved energy but persistent anxiety, elevated heart rate and thirst after a short trial.
Reported use in this account
- Product
- Product labeled urolithin A
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One week
Other exposures described: Escitalopram; Propranolol started after symptoms; Lorazepam
PCOS, pre-existing illness and subsequent medication changes complicate attribution. The title's claim of nervous-system damage was not clinically verified.
Read the original accountNo clear change: reported experiences
Temporary fatigue with no noticeable benefit
A separate commenter reported increased tiredness that was temporary, without a benefit they could detect.
Amount, frequency, route and duration could not be confirmed for this account.
This is a short individual comment, not the outcome of the surrounding poll or a measure of cellular effects.
Read the original accountApproval status
Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.
No FDA-approved drug use
Urolithin A has human supplement-style trials and biomarker outcomes, but no FDA-approved drug indication for mitochondrial health, muscle function, or aging.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether effects persist or translate into less disability or disease
- Whether independent trials reproduce sponsor-linked findings
- Long-term safety across diverse populations
- Which people, if any, have a clinically meaningful response
Summary
Urolithin A has promising early human work, but mixed endpoints and a sponsor-heavy evidence base make it a research candidate—not a proven anti-aging therapy.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRandomized urolithin A trial in older adults
Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.
- pubmedRandomized trial in middle-aged adults
Industry-sponsored study of muscle performance and mitochondrial biomarkers.
- pubmedFirst-in-human urolithin A study
Early study establishing bioavailability, short-term tolerability, and biomarker effects.
- fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.